Home / Resource Library / Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naive follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis
Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naive follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis